Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

SIMPLE SUMMARY: Bladder cancer is the second most common urologic malignancy. Current standard of care for muscle-invasive bladder cancer is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy. There is an unmet need to predict which patients will benefit from neoadjuvant chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagi, Hiroko, Kwenda, Elizabeth, Ramnaraign, Brian H., Chatzkel, Jonathan A., Brisbane, Wayne G., O’Malley, Padraic, Crispen, Paul L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817944/
https://www.ncbi.nlm.nih.gov/pubmed/36612164
http://dx.doi.org/10.3390/cancers15010168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817944/
https://www.ncbi.nlm.nih.gov/pubmed/36612164
http://dx.doi.org/10.3390/cancers15010168

Ejemplares similares